New! Sign up for our free email newsletter.
Science News
from research organizations

Progress Toward An Antitumor Vaccine

Date:
June 14, 2007
Source:
John Wiley & Sons, Inc.
Summary:
A team has found a way to bind a molecule that is typical for tumors to a carrier protein without irritating the immune system. Their method is based on an immunocompatible connection by way of a sulfur atom, namely, a thioether.
Share:
FULL STORY

How can we induce the body to use its own weapon, the immune system, to battle cancer? In principle, by the same means used against infectious diseases: immunization. The production of a selective vaccine is not a trivial task, however. A team led by Horst Kunst at the University of Mainz has now found a way to bind a molecule that is typical for tumors to a carrier protein without irritating the immune system. As they report in the journal Angewandte Chemie, their method is based on an immunocompatible connection by way of a sulfur atom, namely, a thioether.

Epithelial tumor cells have unusually large amounts of mucin MUC1 on their surface. This MUC1, in comparison with its “normal” cousins, is also modified in a very characteristic manner. Mucins are mucilaginous substances that protect the surfaces of mucus membranes. They are glycoproteins—macromolecules with a central protein chain and long side chains made of polysaccharides. The modified MUC1 would be a good target molecule (antigen) for antibodies in immunological antitumor therapy.

The difficulty with this approach is that such sugar-containing compounds are completely ineffective at stimulating the immune system to form antibodies. “Immunization is only successful if the vaccine is anchored to an immunizing carrier protein by means of a spacer,” explains Kunz. This would be very easy to accomplish with polysaccharides, but turns out to be very complicated with glycoproteins, because the protein portion of the molecule has many reactive groups that are attacked in the coupling reaction. “In addition,” says Kunz, “many of the structures that make suitable anchors are themselves highly immunogenic, which can suppress the immune response against the true target, the glycoprotein.”

This team has now found a good anchoring technique: Their anchor is a thioether (two carbon atoms coupled together through a sulfur atom). To this end, the carrier protein is first equipped with a spacer, which has an allyl group (two carbon atoms attached by a double bond) at its end. The glycopeptide is coupled to a building block that causes thiols (sulfur–hydrogen groups) to protrude from the molecule. In the next, light-initiated (photochemical) reaction, only the desired thioether bonds are formed—no side reactions occur at other locations in the peptide chain.

“Synthetic glycopeptide antigens containing structural elements typical of tumors in the sugar as well as the protein segment,” explains Kunz, “can thus be attached to the carrier protein in a controlled fashion. The largely nonimmunogenic thioether bridges could clear the way for the development of vaccines for immunization against tumor cells.”


Story Source:

Materials provided by John Wiley & Sons, Inc.. Note: Content may be edited for style and length.


Cite This Page:

John Wiley & Sons, Inc.. "Progress Toward An Antitumor Vaccine." ScienceDaily. ScienceDaily, 14 June 2007. <www.sciencedaily.com/releases/2007/06/070613102231.htm>.
John Wiley & Sons, Inc.. (2007, June 14). Progress Toward An Antitumor Vaccine. ScienceDaily. Retrieved March 28, 2024 from www.sciencedaily.com/releases/2007/06/070613102231.htm
John Wiley & Sons, Inc.. "Progress Toward An Antitumor Vaccine." ScienceDaily. www.sciencedaily.com/releases/2007/06/070613102231.htm (accessed March 28, 2024).

Explore More

from ScienceDaily

RELATED STORIES